Daniel J. Moore
Chairman, LivaNova PLC
Dan Moore is Chairman of the Board of LivaNova, the company formed by the merger of Cyberonics and Sorin. Dan was President and Chief Executive Officer of Cyberonics from 2007 through the merger in 2015. During his tenure, Cyberonics quickly resumed meaningful epilepsy revenue growth and achieved profitability after approximately 20 years of losses. Net sales for fiscal year 2015 were $292 million resulting in adjusted operating income of approximately $99 million. Under the director of Mr. Moore and his senior management team, Cyberonics, with approximately 650 employees world-wide, focused on its core expertise in neuromodulation, other medical devices for epilepsy, and expanding the Vagus Never Stimulation (VNS) Therapy franchise, which is FDA-approved for the treatment of refractory epilepsy and treatment-resistant depression. He spearheaded strategic investments in growth areas beyond epilepsy, including chronic heart failure and obstructive sleep apnea, leading to the merger with Sorin to form LivaNova.
Mr. Moor joined Cyberonics from Boston Scientific where he held positions in sales, marketing and senior management in the United States and in Europe. In his last position at Boston Scientific, he served as President, International Distributor Management. Prior to this position, he was President, Inter-Continental, the fourth largest business unit of Boston Scientific with more than 1,000 global employees and revenues exceeding $700 million. Mr. Moore began his career with Procter and Gamble after graduating from Harvard College. He also earned an MBA from Boston University.
In addition to LivaNova, he serves on the boards of GI Dynamics (GID:ASX), BrainScope Company, Inc. (Chair), BioHouston Executive Committee, Weldon School of Biomedical Engineering Advisory Board at Purdue University, the Epilepsy Foundation of America and the Medical Device Manufacturers Association (MDMA) (immediate past-Chair). Pat board positions include Smiling Kids, Inc., the Epilepsy Foundation of Texas (past-Chair), the Epilepsy Foundation of Texas - Houston (past-President), Medical Device Innovation Consortium (MDIC), Topera, Inc. (acquired by Abbot) and TriVascular, Inc. (acquired by Endologix).